Schonfeld Strategic Advisors LLC Beam Therapeutics Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $14.6 Billion
- Q2 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 30,517 shares of BEAM stock, worth $693,956. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,517
Previous 48,698
37.33%
Holding current value
$693,956
Previous $1.61 Million
55.53%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding BEAM
# of Institutions
229Shares Held
71.8MCall Options Held
283KPut Options Held
233K-
Farallon Capital Management LLC San Francisco, CA7.91MShares$180 Million0.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$180 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$174 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.63MShares$173 Million1.63% of portfolio
-
Arch Venture Management, LLC Chicago, IL5.44MShares$124 Million74.72% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.6B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...